Trial Profile
Retrospective study of afatinib therapy in non small cell lung cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2018 New trial record
- 01 Sep 2018 Results published in the Anticancer Research